JP2022501327A5 - - Google Patents

Info

Publication number
JP2022501327A5
JP2022501327A5 JP2021512742A JP2021512742A JP2022501327A5 JP 2022501327 A5 JP2022501327 A5 JP 2022501327A5 JP 2021512742 A JP2021512742 A JP 2021512742A JP 2021512742 A JP2021512742 A JP 2021512742A JP 2022501327 A5 JP2022501327 A5 JP 2022501327A5
Authority
JP
Japan
Prior art keywords
compound
compound according
pharmaceutically acceptable
acceptable salt
treatment
Prior art date
Application number
JP2021512742A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020051356A5 (https=
JP2022501327A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/049784 external-priority patent/WO2020051356A1/en
Publication of JP2022501327A publication Critical patent/JP2022501327A/ja
Publication of JPWO2020051356A5 publication Critical patent/JPWO2020051356A5/ja
Publication of JP2022501327A5 publication Critical patent/JP2022501327A5/ja
Pending legal-status Critical Current

Links

JP2021512742A 2018-09-07 2019-09-05 イミダゾキノリン化合物およびその使用 Pending JP2022501327A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862728556P 2018-09-07 2018-09-07
US62/728,556 2018-09-07
PCT/US2019/049784 WO2020051356A1 (en) 2018-09-07 2019-09-05 Imidazoquinoline compounds and uses thereof

Publications (3)

Publication Number Publication Date
JP2022501327A JP2022501327A (ja) 2022-01-06
JPWO2020051356A5 JPWO2020051356A5 (https=) 2022-07-04
JP2022501327A5 true JP2022501327A5 (https=) 2022-07-04

Family

ID=69722888

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021512742A Pending JP2022501327A (ja) 2018-09-07 2019-09-05 イミダゾキノリン化合物およびその使用

Country Status (9)

Country Link
US (1) US20210214354A1 (https=)
EP (2) EP4306523A3 (https=)
JP (1) JP2022501327A (https=)
KR (1) KR20210074290A (https=)
CN (1) CN113164460A (https=)
AU (1) AU2019335366A1 (https=)
CA (1) CA3111786A1 (https=)
ES (1) ES2963112T3 (https=)
WO (1) WO2020051356A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105899539B (zh) 2014-01-10 2021-11-09 博笛生物科技有限公司 用于免疫疗法的化合物和组合物
EP3166976B2 (en) 2014-07-09 2026-04-08 Birdie Biopharmaceuticals Inc. Anti-pd-l1 combinations for treating tumors
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CN115252792A (zh) 2016-01-07 2022-11-01 博笛生物科技有限公司 用于治疗肿瘤的抗-egfr组合
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技(北京)有限公司 用于治疗肿瘤的抗-cd20组合
KR102726248B1 (ko) 2016-07-07 2024-11-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
IL312120B2 (en) 2017-06-23 2025-06-01 Birdie Biopharmaceuticals Inc Pharmaceutical compositions
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
CN115916342A (zh) * 2020-07-08 2023-04-04 普渡研究基金会 用于治疗纤维化疾病和癌症的化合物、组合物和方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US689338A (en) * 1901-03-29 1901-12-17 Nat Faucet Company Tapping-bung.
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
EP1667694B1 (en) * 2003-09-05 2010-04-28 Anadys Pharmaceuticals, Inc. Tlr7 ligands for the treatment of hepatitis c
US20080213308A1 (en) * 2004-09-14 2008-09-04 Nicholas Valiante Imidazoquinoline Compounds
US8728486B2 (en) * 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
WO2013033345A1 (en) * 2011-08-30 2013-03-07 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
MX377916B (es) * 2014-04-22 2025-03-10 Hoffmann La Roche Compuestos 4-amino-imidazoquinolina.
CN105233291A (zh) * 2014-07-09 2016-01-13 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
EP3166976B2 (en) * 2014-07-09 2026-04-08 Birdie Biopharmaceuticals Inc. Anti-pd-l1 combinations for treating tumors
CN105732635A (zh) * 2014-12-29 2016-07-06 南京明德新药研发股份有限公司 一类Toll样受体7激动剂
CN115350279A (zh) * 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合

Similar Documents

Publication Publication Date Title
JP2022501327A5 (https=)
JP2021522249A5 (https=)
JP2022031403A5 (https=)
JP2020037585A5 (https=)
JP2020125349A5 (https=)
JPWO2020051356A5 (https=)
JP2020532547A5 (https=)
JP2012529486A5 (https=)
JP2018070614A5 (https=)
JP2015536986A5 (https=)
JP2021534158A5 (https=)
JP2009538327A5 (https=)
RU2007101236A (ru) Новые гидантоиновые производные для лечения обструктивных заболеваний дыхательных путей
JP2005508337A5 (https=)
JP2015517523A5 (https=)
RU2014141934A (ru) Комбинация производного 6-оксо-1,6-дигидро-пиридазина, которая обладает противораковым действием с другими противоопухолевыми соединениями
JP2019529460A5 (https=)
JP2007501284A5 (https=)
JPWO2020037092A5 (https=)
JPWO2020037091A5 (https=)
JP2022169780A5 (https=)
RU2017124371A (ru) Комбинация производного 6-оксо-1,6-дигидро-пиридазина, обладающего противораковой активностью, с производным хиназолина
CN105616024B (zh) 口内支撑吸唾器
Yang et al. Advances in development of antiviral strategies against respiratory syncytial virus
Steele Forum on the tonsil and adenoid problem in orthodontics An otolaryngologist views the tonsil and adenoid problem